Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

G-7 nations expected to pledge 1B vaccine doses for world

The Group of Seven nations are set to commit to sharing at least 1 billion coronavirus shots with the world, British Prime Minister Boris Johnson announced Thursday, with half coming from the U.S. and 100 million from the U.K. as President Joe Biden urged allies to join in speeding the pandemic’s end and bolstering the strategic position of the world’s wealthiest democracies.

Johnson’s announcement on the eve of the G-7 leaders’ summit in England came hours after Biden committed to donating 500 million COVID-19 vaccine doses and previewed a coordinated effort by the advanced economies to make vaccination widely and speedily available everywhere.

“We’re going to help lead the world out of this pandemic working alongside our global partners,” Biden said, adding that on Friday the G-7 nations would join the U.S. in outlining their vaccine donation commitments. The G-7 also includes Canada, France, Germany, Italy and Japan.

Source: AP

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!